Three-Drug attack on stomach cancer shows promise
NCT ID NCT06962137
Summary
This study is testing whether adding a new targeted drug called Zolbetuximab to standard chemotherapy improves survival for people with advanced stomach or esophageal cancer. It's for patients whose cancer has a specific protein marker called CLDN18.2 and whose disease has progressed after initial treatment. Researchers will compare results to historical data from patients who received only standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER ADENOCARCINOMA METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AZ Delta Roeselare
NOT_YET_RECRUITINGRoeselare, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cliniques Universitaires Saint-Luc Brussels
NOT_YET_RECRUITINGBrussels, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
HUB
NOT_YET_RECRUITINGBrussels, Belgium
Contact Email: •••••@•••••
-
UZ Gent
NOT_YET_RECRUITINGGhent, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UZ Leuven
RECRUITINGLeuven, 3000, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UZA
NOT_YET_RECRUITINGAntwerp, Belgium
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.